Australian men with higher risk prostate cancer now have access to a nuclear medicine scan to help detect and treat metastatic disease, after it was listed on the Medical Benefits Schedule (MBS) from 1st July 2022.
In 2021 over 18,000 Australian men were diagnosed with prostate cancer, resulting in over 3,000 lives being lost – and making prostate cancer Australia’s second most common cause of cancer death in men.
Australia has led the world in the research and development of this scan using a relatively novel radiotracer, known as PSMA PET/CT. The availability of funding for PSMA PET/CT scans is a major win for patients, who until now have either paid for these tests themselves or found the scans unobtainable because of the cost. The Australasian Association of Nuclear Medicine Specialists (AANMS) welcomed the MBS funding which it says will help improve outcomes for thousands of men with a higher risk prostate cancer. “PSMA PET/CT imaging enables highly specific detection of tumour sites throughout the body with far greater sensitivity compared to other conventional scans. This enables doctors to make more accurate
diagnoses than is currently possible with other MBS-funded scans, and which in turn can be lifesaving for some patients,” said AANMS President, Associate Professor Sze Ting Lee.
The AANMS has worked closely with partners to achieve this important milestone in the diagnosis and treatment of prostate cancer.
“We would like to acknowledge the work of Dr Robert Ware from Cyclotek in generating the original funding application and their ongoing support in steering the application with AANMS during the tenure of my predecessor, Dr Geoff Schembri. We also extend our thanks to all those who supported the application, including AstraZeneca who sponsored the submission,” Associate Professor Lee said.
With funding now available, AANMS will work closely with other key stakeholders to ensure that patients are appropriately referred for these tests.
Australian Health Journal spoke with Associate Professor Lee and Dr Geoff Schembri on the MBS listing and the efforts to get it listed.
About AANMS
The AANMS is a peak body representing medical practitioners working in the field of nuclear medicine diagnosis and therapy. It works to promote and advance the clinical practice of nuclear medicine, which can be used to both diagnose and treat patients with a range of health conditions including the leading causes of death in Australia; cancer, dementia, heart and lung diseases; as well as renal, endocrine and paediatric disorders. Together with government and other stakeholders, AANMS is working to build a strong and sustainable nuclear medicine sector in Australia in order to optimise health outcomes for Australia patients.
-
Intervention in hearing loss for patients
In her role as an audiologist and trainer, Lauren McNee emphasises the urgency of addressing sudden hearing loss, highlighting the time-sensitive nature of available treatment options. She advises healthcare professionals, including GPs, pharmacists, primary care nurses and specialists, to remain vigilant for subtle signs of hearing loss in their patients. Such signs may include difficulty following prescription guidelines, miscommunication during conversations, or non-verbal cues like a tilt of the head or asking for repetitions.
-
Sovereign capability uplifted
Skilled labour, in particular skilled in the manufacture of MTP products, namely competency in Good Manufacturing Practice (GMP), was identified as one of the key priorities, according to Jarrod Belcher, Director of the REDI Program at MTPConnect. Through a competitive process, MTPConnect selected additional industry training providers to deliver new programs addressing key skills gaps in the sector workforce.
Launched in September 2022, one of these programs is GMP Uplift developed by the Centre for Biopharmaceutical Excellence (CBE). CBE bring experience across large and small Biologics, Pharmaceuticals and Regenerative Medicine companies, both in consulting and GMP related enterprise training. CBE staff also have extensive experience in GMP operations, compliance, auditing and QMS design, a wide industry network for guest lecturers and readily available case studies.
-
Making clinical trials participant friendly
Clinical trials are essential in developing new, improved, and more effective treatments and interventions. Without trials, researchers and professionals in the field cannot properly determine whether these new treatments and interventions are safe and effective.
The Clinials platform is geared towards patient centric trials and reducing site burden. The aim is to accelerate lifesaving medicines coming to market by connecting participants and researchers. The platform allows participants to come to researchers with their eligibility in hand among other capabilities.
